Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Co-administered AD-2021 and AD-2022 in Primary Hypercholesterolemia and Essential Hypertension
NCT06448962Phase 3Completed
- Sponsor
- Addpharma, Inc.
- Start
- Oct 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ezetimibe, atorvastatin, amlodipine in hypercholesterolemia, essential hypertension, sponsored by Addpharma, Inc.. Started Oct 2020; status: completed.
02
Drugs
ezetimibeatorvastatinamlodipine
03
Conditions
hypercholesterolemiaessential hypertension
Beyond the preview
Go deeper on NCT06448962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448962.